COSCIENS Biopharma Inc. (LON:0UGB)
London
· Delayed Price · Currency is GBP · Price in CAD 4.200
-0.050 (-1.18%)
At close: Jan 22, 2025
COSCIENS Biopharma Revenue
COSCIENS Biopharma had revenue of $1.50M USD in the quarter ending March 31, 2025, a decrease of -27.08%. This brings the company's revenue in the last twelve months to $9.03M, up 36.51% year-over-year. In the year 2024, COSCIENS Biopharma had annual revenue of $9.59M with 34.22% growth.
Revenue (ttm)
$9.03M
Revenue Growth
+36.51%
P/S Ratio
1.14
Revenue / Employee
$225.75K
Employees
40
Market Cap
7.98M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.59M | 2.44M | 34.22% |
| Dec 31, 2023 | 7.14M | -7.43M | -50.98% |
| Dec 31, 2022 | 14.57M | 9.31M | 177.03% |
| Dec 31, 2021 | 5.26M | 1.61M | 44.03% |
| Dec 31, 2020 | 3.65M | 3.12M | 586.47% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 42.56B |
| Shell | 217.54B |
| HSBC Holdings | 44.89B |
| Unilever | 50.25B |
| Rolls-Royce Holdings | 18.91B |
| British American Tobacco p.l.c. | 25.87B |
| Rio Tinto Group | 42.86B |
| RELX PLC | 9.43B |
COSCIENS Biopharma News
- 5 weeks ago - COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders - GlobeNewsWire
- 7 weeks ago - COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 3 months ago - COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 3 months ago - COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order - GlobeNewsWire
- 3 months ago - COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents - Newsfile Corp
- 4 months ago - COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product - GlobeNewsWire
- 6 months ago - COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization - GlobeNewsWire
- 8 months ago - COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs - GlobeNewsWire